In This Article:
As the U.S. stock market faces heightened volatility amid escalating trade tensions and economic uncertainty, major indices like the Dow Jones and Nasdaq have entered correction and bear market territories, respectively. In such turbulent times, identifying stocks that are trading below their intrinsic value can be a strategic approach for investors seeking potential opportunities in undervalued assets.
Top 10 Undervalued Stocks Based On Cash Flows In The United States
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| NBT Bancorp (NasdaqGS:NBTB) | $39.65 | $78.73 | 49.6% |
| International Paper (NYSE:IP) | $49.18 | $98.19 | 49.9% |
| CI&T (NYSE:CINT) | $5.68 | $11.36 | 50% |
| Range Resources (NYSE:RRC) | $38.07 | $75.64 | 49.7% |
| Five9 (NasdaqGM:FIVN) | $25.24 | $50.27 | 49.8% |
| Elastic (NYSE:ESTC) | $82.21 | $162.43 | 49.4% |
| RXO (NYSE:RXO) | $15.77 | $31.23 | 49.5% |
| ZEEKR Intelligent Technology Holding (NYSE:ZK) | $23.70 | $46.94 | 49.5% |
| Sotera Health (NasdaqGS:SHC) | $10.73 | $21.24 | 49.5% |
| AeroVironment (NasdaqGS:AVAV) | $117.59 | $232.32 | 49.4% |
Here's a peek at a few of the choices from the screener.
Lantheus Holdings
Overview: Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products for heart, cancer, and other diseases globally with a market cap of approximately $6.68 billion.
Operations: The company's revenue is primarily derived from its diagnostic kits and equipment segment, which generated approximately $1.53 billion.
Estimated Discount To Fair Value: 45.9%
Lantheus Holdings is trading at a significant discount to its estimated fair value, with shares priced at US$97.21 against a fair value estimate of US$179.58. Revenue is forecasted to grow faster than the broader U.S. market, and earnings are expected to increase by 15.81% annually, surpassing market averages. Recent financials show revenue growth but a slight decline in net income year-over-year, while strategic moves include share repurchases and acquiring Evergreen Theragnostics for US$250 million to enhance radiopharmaceutical capabilities.
Viant Technology
Overview: Viant Technology Inc. is an advertising technology company with a market cap of $860.33 million.
Operations: The company generates revenue through its Internet Information Providers segment, totaling $289.24 million.
Estimated Discount To Fair Value: 37.6%